1. Hypoxia and glucose metabolism assessed by FMISO and FDG PET for predicting IDH1 mutation and 1p/19q codeletion status in newly diagnosed malignant gliomas
- Author
-
Kenta Suzuki, Nobuyuki Kawai, Tomoya Ogawa, Keisuke Miyake, Aya Shinomiya, Yuka Yamamoto, Yoshihiro Nishiyama, and Takashi Tamiya
- Subjects
Chromosome 1p and 19q codeletion ,[18F]-Fluoromisonidazole (FMISO) ,[18F]-Fluoro-2-deoxy-d-glucose (FDG) ,Glioma ,IDH mutation ,Hypoxia ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Abstract Background Tumor hypoxia and glycolysis have been recognized as determinant factors characterizing tumor aggressiveness in malignant gliomas. To clarify in vivo hypoxia and glucose metabolism in relation to isocitrate dehydrogenase (IDH) mutation and chromosome 1p and 19q (1p/19q) codeletion status, we retrospectively analyzed hypoxia as assessed by positron emission tomography (PET) with [18F]-fluoromisonidazole (FMISO) and glucose metabolism as assessed by PET with [18F]-fluoro-2-deoxy-d-glucose (FDG) in newly diagnosed malignant gliomas. Methods In total, 87 patients with newly diagnosed supratentorial malignant (WHO grade III and IV) gliomas were enrolled in this study. They underwent PET studies with FMISO and FDG before surgery. The molecular features and histopathological diagnoses based on the 2016 WHO classification were determined using surgical specimens. Maximal tumor-to-normal ratio (TNR) was calculated for FDG PET, and maximal tumor-to-blood SUV ratio (TBR) was calculated for FMISO PET. The PET uptake values in relation to IDH mutation and 1p/19q codeletion status were statistically analyzed. Results In all tumors and malignant astrocytomas, the median FMISO TBR in IDH-wildtype tumors was significantly higher than that in IDH-mutant tumors (P
- Published
- 2021
- Full Text
- View/download PDF